TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12582226

Group type: EXPERIMENTAL
Intervention: Long break group (LB) - 6-week break after lesson 7
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Short break group (SB) - 2-week breaks after lessons 3, 6, and 9
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group - standard behavioral weight loss program with 14 weekly sessions
Number of subjects: 142
Study: 10852458

Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment at doses ranging from 0.25-3.5 mg weekly for 1-3 years
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment at doses ranging from 0.25-1 mg weekly for 1-6 months
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment at doses ranging from 1-2 mg weekly for 6-12 months and 3-3.5 mg weekly for 18-24 months
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment at doses ranging from 1-2 mg weekly for 1-6 months and 3 mg weekly for 12 months
Number of subjects: 110
Study: 9356099

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infused intravenously at a rate of 0.3 g/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) infused intravenously at a rate of 5 g/kg
Number of subjects: 24
Study: 8449049

Group type: EXPERIMENTAL
Intervention: Albuterol by nebulizer plus placebo by inhaler (n = 20)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Albuterol by inhaler plus placebo by nebulizer (n = 15)
Number of subjects: 35
Study: 3756264

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29873864

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (personalized oral hygiene instructions, subgingival scaling, and root planing per quadrant)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (received equal treatment after the study period)
Number of subjects: 69
Study: 26842790

Group type: EXPERIMENTAL
Intervention: Nicotine e-cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine-free e-cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 24878942

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 22244462

Group type: EXPERIMENTAL
Intervention: Standard monitoring plus capnography
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard monitoring (control group)
Number of subjects: 27
Study: 20190383

Group type: EXPERIMENTAL
Intervention: 9 minutes of side‐alternating whole‐body vibration (WBV; Vibraflex Home Edition II, Orthometrix Inc) per school day in addition to their school physiotherapy program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (continued school physiotherapy program unchanged)
Number of subjects: 20
Study: 18779620

Group type: EXPERIMENTAL
Intervention: Prevalent diabetes
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 1554
Study: 16138517

Group type: EXPERIMENTAL
Intervention: Pedometer plus education (PE)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Pedometer (P)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 87
Study: 11823390

Group type: EXPERIMENTAL
Intervention: Intraosseous lidocaine (IL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous nalbuphine and propacetamol (NP)
Number of subjects: 100
Study: 10065346

Group type: EXPERIMENTAL
Intervention: Sustained-release lithium carbonate (HP matrix)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained-release lithium carbonate (L matrix)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-fat/high-protein diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 12
Study: 7668664

Group type: EXPERIMENTAL
Intervention: Clarion cochlear implant
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nucleus implant
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ineraid device
Number of subjects: 50
Study: 2343859

Group type: EXPERIMENTAL
Intervention: Certified mailing in phase 1
Number of subjects: 12233

Group type: EXPERIMENTAL
Intervention: Repeat certified mailing to nonrespondents
Number of subjects: 12233

Group type: COMPARATOR
Intervention: Altering the physical appearance of the envelope and using other postal rates
Number of subjects: 12233
Study: 6777233

Group type: EXPERIMENTAL
Intervention: Intravenous hyperalimentation (IVH) with total bowel rest
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (prednisone 40 mg/day)
Number of subjects: 36
Study: 30635497

Group type: EXPERIMENTAL
Intervention: Interscalene block (ISB)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Costoclavicular block (CCB)
Number of subjects: 44
Study: 28655016

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 504

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 504
Study: 25879794

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isotonic saline injection (control)
Number of subjects: 12
Study: 24015983

Group type: EXPERIMENTAL
Intervention: CARE program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 50
Study: 21868730

Group type: EXPERIMENTAL
Intervention: 3 mg recombinant tissue-type plasminogen activator (rtPA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 19154802

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (EM) 600 mg/day, n=18
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo, n=14
Number of subjects: 32
Study: 17356094

Group type: EXPERIMENTAL
Intervention: 2.5 mg bid of nebulized recombinant human deoxyribonuclease (rhDNase)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 14681504

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 3047

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3047

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 3047

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3047
Study: 11106230

Group type: EXPERIMENTAL
Intervention: XR9576 2.0 mg/kg i.v.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XR9576 > or = 200 mg/volunteer p.o.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XR9576 (various doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10173443

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation (n = 43)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Outpatient follow-up (n = 42)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation
Number of subjects: 85
Study: 8443849

Group type: EXPERIMENTAL
Intervention: Nasal ketamine 6 mg.kg‐1
Number of subjects: 86

Group type: COMPARATOR
Intervention: Promethazine and meperidine 1 mg.kg‐1 each (Control)
Number of subjects: 86
Study: 3784306

Group type: EXPERIMENTAL
Intervention: Ketoprofen (K)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Indomethacin (I)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 2
Study: 31023553

Group type: EXPERIMENTAL
Intervention: Validation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Invalidation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Technical language
Number of subjects: 132

Group type: COMPARATOR
Intervention: Plain language
Number of subjects: 132
Study: 30629148

Group type: EXPERIMENTAL
Intervention: PAMVAC-GLA-SE
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PAMVAC with Alhydrogel or GLA-based adjuvants
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All PAMVAC formulations
Number of subjects: 36
Study: 28110412

Group type: EXPERIMENTAL
Intervention: KDIGO bundle (optimization of volume status and hemodynamics, avoidance of nephrotoxic drugs, preventing hyperglycemia)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: KDIGO bundle
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 25777987

Group type: EXPERIMENTAL
Intervention: Web-based training for DMV staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (DMV staff without training)
Number of subjects: 0
Study: 23804191

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 1754

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 1754
Study: 21094532

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) service
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Clinical keyworker relationship
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Absence of work history
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Care needs being met
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Social disability and remission
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Same sex as the client
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Duration of the relationship
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Client's increasing anxiety
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Client and professional ratings
Number of subjects: 312
Study: 19846001

Group type: EXPERIMENTAL
Intervention: PEEP 0 cm H(2)O
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP 5 cm H(2)O
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP 10 cm H(2)O
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group at PEEP 0 cm H(2)O
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group at PEEP 5 cm H(2)O
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group at PEEP 10 cm H(2)O
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP levels 0 to 10 cm H(2)O
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group at all PEEP levels
Number of subjects: 30
Study: 16452919

Group type: EXPERIMENTAL
Intervention: Dealcoholised red wine (DRW)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Red wine (RW)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 45
Study: 15079128

Group type: EXPERIMENTAL
Intervention: Chemotherapy (31 patients)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (34 patients)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Surgery (control group, 45 patients)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Surgery (control group)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Postoperative treatment (overall)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (overall)
Number of subjects: 110
Study: 11463561

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin 100 mg/m² on day 1 and etoposide 120 mg/m² on days 1-3 for six cycles)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 66
Study: 12526358

Group type: EXPERIMENTAL
Intervention: rIFN alpha‐2b 1 x 10(6)U per day, i.m., for three days
Number of subjects: 146

Group type: COMPARATOR
Intervention: Traditional combined therapy with a predominance of balanced solution
Number of subjects: 146
Study: 8070497

Group type: EXPERIMENTAL
Intervention: 0.5 mg of the ACE inhibitor perindoprilat
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 2738728

Group type: EXPERIMENTAL
Intervention: Transparent adhesive dressing (TAD), n = 6
Number of subjects: 13

Group type: COMPARATOR
Intervention: Routine care (Control), n = 7
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: TAD, n = 6
Number of subjects: 13
Study: 29420063

Group type: EXPERIMENTAL
Intervention: Random spice isolates producing enterotoxin at levels of 4 to 16 ng/mL
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: D95°C levels of spores from four randomly selected spice isolates
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: One spice isolate with D95°C
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Five of the 43 isolates
Number of subjects: 247
Study: 26139307

Group type: EXPERIMENTAL
Intervention: Golimumab (50 mg subcutaneously every 4 weeks)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 23915113

Group type: EXPERIMENTAL
Intervention: Interferon beta 1b (IFNB)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Natalizumab (NTZ)
Number of subjects: 19
Study: 21668284

Group type: EXPERIMENTAL
Intervention: Articaine HCl
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Prilocaine HCl
Number of subjects: 162

Group type: COMPARATOR
Intervention: Maxillary infiltration
Number of subjects: 162

Group type: COMPARATOR
Intervention: Mandibular nerve block
Number of subjects: 162
Study: 19578678

Group type: COMPARATOR
Intervention: Zero minutes of nicotine abstinence
Number of subjects: 201

Group type: COMPARATOR
Intervention: 30 minutes of nicotine abstinence
Number of subjects: 201

Group type: COMPARATOR
Intervention: 60 minutes of nicotine abstinence
Number of subjects: 201
Study: 16913264

Group type: EXPERIMENTAL
Intervention: Desloratadine, 5 mg
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Fexofenadine, 180 mg
Number of subjects: 722

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 722
Study: 15578470

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 21
Study: 11453957

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, average daily dose 2.4 IU (SD 0.86)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 12
Study: 9209724

Group type: EXPERIMENTAL
Intervention: Continuing treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Successful tapering off medication
Number of subjects: 35
Study: 9113123

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 259

Group type: COMPARATOR
Intervention: Antiemetic cocktail (metoclopramide, dexamethasone, lorazepam)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Tropisetron plus placebo
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Tropisetron plus dexamethasone
Number of subjects: 259
Study: 3042317

Group type: EXPERIMENTAL
Intervention: Clofibrate (1.5 g/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 31679120

Group type: EXPERIMENTAL
Intervention: 40 mg Oxycodone Tamper-Resistant Tablet (OTR)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 40 mg OXYCONTIN® (OXY)
Number of subjects: 38
Study: 30942008

Group type: EXPERIMENTAL
Intervention: Umbilical moxibustion, 2 times a week for 12 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Follow-up after treatment (Observation group)
Number of subjects: 116
Study: 28268074

Group type: EXPERIMENTAL
Intervention: Inactivated zoster vaccine (ZVIN), 4-dose regimen (∼30 days between doses)
Number of subjects: 80
Study: 26536057

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Psychotherapy (GPT)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Individual Clinical Management (CM)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Methylphenidate with GPT
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Methylphenidate with CM
Number of subjects: 419
Study: 23216089

Group type: EXPERIMENTAL
Intervention: New research coding strategy designed to introduce the virtual channel effect
Number of subjects: 9

Group type: COMPARATOR
Intervention: MP3(000™)
Number of subjects: 9
Study: 17012141

Group type: EXPERIMENTAL
Intervention: Oral beta‐1,3/1,6‐glucan 700 mg (Group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral beta‐1,3/1,6‐glucan 1400 mg (Group 2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 21
Study: 12709037

Group type: EXPERIMENTAL
Intervention: Aggressive multiple-infusion episode-based protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard alternate-day prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized escalating dose and frequency of routine replacement infusions of factor concentrate
Number of subjects: 0
Study: 10427667

Group type: EXPERIMENTAL
Intervention: Pulsed Doppler measurements of the fetal ductus arteriosus
Number of subjects: 418
Study: 7572679

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 6595

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595
Study: 1675048

Group type: EXPERIMENTAL
Intervention: Apraclonidine hydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Apraclonidine and timolol (combined)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Apraclonidine alone or timolol alone
Number of subjects: 20
Study: 7015795

Group type: EXPERIMENTAL
Intervention: Captopril (75-450 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Captopril (75-450 mg daily) + Hydrochlorothiazide (50-100 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo + Hydrochlorothiazide (50-100 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 24
Study: 31774483

Group type: EXPERIMENTAL
Intervention: Cognitive aids
Number of subjects: 144

Group type: COMPARATOR
Intervention: No cognitive aids (Control)
Number of subjects: 144
Study: 29973172

Group type: EXPERIMENTAL
Intervention: Newborn Behavioral Observation (NBO) method during home visits from 3 weeks to 3 months postpartum
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: NBO method
Number of subjects: 2800
Study: 28486709

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT; lozenge, patch, both)
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Bupropion (alone or with nicotine lozenge)
Number of subjects: 1122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1122
Study: 25600258

Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation with biofeedback capability
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 0
Study: 24025626

Group type: EXPERIMENTAL
Intervention: Cobalamin supplementation (400 μg hydroxycobalamin intramuscularly)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sham injection (placebo)
Number of subjects: 79
Study: 20717875

Group type: EXPERIMENTAL
Intervention: HMC05 (500 mg tablets, 3 times daily for 4 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (500 mg tablets, 3 times daily for 4 weeks)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HMC05
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18670888

Group type: EXPERIMENTAL
Intervention: Intervention group (socio-educational workshops)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 404
Study: 15705087

Group type: EXPERIMENTAL
Intervention: Prophylactic tamsulosin initiated 2 weeks before implantation and continued until IPSS returned to normal
Number of subjects: 130

Group type: COMPARATOR
Intervention: No prophylactic alpha-blocker
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 103Pd isotope
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 125I isotope
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Prophylactic alpha-blockers
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Supplemental radiotherapy and/or androgen deprivation therapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Maximum IPSS after implantation
Number of subjects: 130
Study: 12851876

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 10‐mg therapy for 48 weeks
Number of subjects: 694
Study: 10778338

Group type: EXPERIMENTAL
Intervention: Long-stretch compression bandage
Number of subjects: 43

Group type: COMPARATOR
Intervention: Short-stretch compression bandage
Number of subjects: 43
Study: 8740244

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg for 1 month, 20 mg for 1 month, 40 mg for 4 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1880344

Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 37

Group type: COMPARATOR
Intervention: Topical timolol
Number of subjects: 37
Study: 6761123

Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol 160 mg twice daily
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol
Number of subjects: 4000
Study: 30863632

Group type: EXPERIMENTAL
Intervention: High-dose IQP-AE-103
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Low-dose IQP-AE-103
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: IQP-AE-103
Number of subjects: 108
Study: 28209040

Group type: EXPERIMENTAL
Intervention: COPD community integrated management system
Number of subjects: 460

Group type: COMPARATOR
Intervention: Essential diagnosis and treatment services
Number of subjects: 460
Study: 26022508

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) - bolus dose of 0.5 µg·kg‐1 within 10 min, maintenance dose of 0.5 µg·kg‐1·h‐1
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Etomidate (ETO) - bolus dose of 0.3 mg·kg‐1 without maintenance dose
Number of subjects: 99

Group type: COMPARATOR
Intervention: Routine anesthetics (Control Group)
Number of subjects: 99
Study: 24316712

Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 15

Group type: COMPARATOR
Intervention: Delayed implant placement
Number of subjects: 15